The development component of the UCSD CFAR is designed to facilitate and encourage new investigators and new ideas in HIV and AIDS research. The intent is to optimize opportunities for productive research by providing immediate financial support in association with resource support provided by the core facilities. Three categories of developmental grants will be supported although, the number and type of these categories are flexible. Presently, the three categories are: 1) Investigators new to AIDS research; 2) Feasibility studies and 3) Evolving research opportunities. Requests for submission of developmental grants will be advertised through the Administrative Core twice a year, for funding in January and June. The submissions are evaluated by a review committee which has an evolving membership. Additional members from related fields will be added as applications for developmental funds become increasingly diverse in scope. Merit is the driving criterion for making the awards; however, fostering the development of junior and minority investigators are two important programmatic goals which are also considered in the prioritization of awards. The amount of the awards given will be increased to $35,000. As part of their awards, investigators are required to provide documentation of publications and peer reviewed funding that results from the developmental awards. They are also required to cite CFAR support in publications which are generated or related to the research performed using CFAR developmental funds. With the growth of the CFAR, we anticipate a greater number of innovative and timely projects will be funded, attracting new members and affiliates who can advance HIV and AIDS research, supported, in part, by developmental funds.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
3P30AI036214-08S1
Application #
6500684
Study Section
Project Start
2001-09-30
Project End
2002-05-31
Budget Start
Budget End
Support Year
8
Fiscal Year
2001
Total Cost
$180,480
Indirect Cost
Name
University of California San Diego
Department
Type
DUNS #
077758407
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Jiang, Wei; Luo, Zhenwu; Martin, Lisa et al. (2018) Drug Use is Associated with Anti-CD4 IgG-mediated CD4+ T Cell Death and Poor CD4+ T Cell Recovery in Viral-suppressive HIV-infected Individuals Under Antiretroviral Therapy. Curr HIV Res 16:143-150
White, Cory H; Beliakova-Bethell, Nadejda; Lada, Steven M et al. (2018) Transcriptional Modulation of Human Endogenous Retroviruses in Primary CD4+ T Cells Following Vorinostat Treatment. Front Immunol 9:603
Innes, Steve; Patel, Kunjal (2018) Noncommunicable diseases in adolescents with perinatally acquired HIV-1 infection in high-income and low-income settings. Curr Opin HIV AIDS 13:187-195
Gianella, Sara; Marconi, Vincent C; Berzins, Baiba et al. (2018) Genital HIV-1 Shedding With Dolutegravir (DTG) Plus Lamivudine (3TC) Dual Therapy. J Acquir Immune Defic Syndr 79:e112-e114
Rhodes, Tim (2018) The becoming of methadone in Kenya: How an intervention's implementation constitutes recovery potential. Soc Sci Med 201:71-79
Morales, Mario; Rafful, Claudia; Gaines, Tommi L et al. (2018) Factors associated with extrajudicial arrest for syringe possession: results of a department-wide survey of municipal police in Tijuana, Mexico. BMC Int Health Hum Rights 18:36
Ben Hamida, Amen; Rafful, Claudia; Jain, Sonia et al. (2018) Non-injection Drug Use and Injection Initiation Assistance among People Who Inject Drugs in Tijuana, Mexico. J Urban Health 95:83-90
Christensen-Quick, Aaron; Chaillon, Antoine; Yek, Christina et al. (2018) Influenza Vaccination Can Broadly Activate the HIV Reservoir During Antiretroviral Therapy. J Acquir Immune Defic Syndr 79:e104-e107
Groessl, Erik J; Ganiats, Theodore G; Hillery, Naomi et al. (2018) Cost analysis of rapid diagnostics for drug-resistant tuberculosis. BMC Infect Dis 18:102
Dillon, Stephanie M; Guo, Kejun; Austin, Gregory L et al. (2018) A compartmentalized type I interferon response in the gut during chronic HIV-1 infection is associated with immunopathogenesis. AIDS 32:1599-1611

Showing the most recent 10 out of 921 publications